ASH 2018 | CLL news from ASH 2018: ibrutinib strikes again!
Stephan Stilgenbauer
Stephan Stilgenbauer, MD, of the University of Ulm, Ulm, Germany, discusses the chronic lymphocytic leukemia (CLL) highlights at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
Related videos
3:04
Anti-CD19 CAR T-cell therapy in combination with ibrutinib for CLL/SLL
Saar Gill
3:04
An exciting era for CAR T-cell therapy
Mohamad Mohty
3:04
Ibrutinib combinations for CLL: iLLUMINATE results & more
Carol Moreno
3:04
JCAR017 for relapsed/refractory CLL
Tanya Siddiqi
3:04
Factors that influence the treatment decision-making of CLL patients
Brian Koffman
